OpusPoint Partners was founded by Michael S. Weiss and Dr. Lindsay Rosenwald in 2009 and remains at the forefront of the revolution in the life science and healthcare industry. Time and money is invested to advance both the biotechnological and life sciences fields with the belief that the investments will be worth it if there is improvement in the way that diseases are diagnosed and the manner in which patients are treated, ultimately reflecting a sympathetic understanding of the needs of the patients.
OpusPoint Partners is sure that under the strong leadership of both Mr. Weiss and Dr. Rosenwald, there will be significant improvements in the healthcare industry in a way that will have a positive impact on the quality of healthcare available for the human race to enjoy.
OpusPoint Partners is just one of many biotechnology companies that were founded by these two dedicated gentlemen over a number of years. All of the companies are reflective of their forty years of accumulated experience and expertise in biotech research with investing.
They readily admit that although the mission is straightforward, the task of transforming the existing healthcare and medical procedures is not easy and requires in addition to funding, the input of time and unwavering commitment with everyone working hard and following ethical standards that would generally be disregarded by other firms, in a quest to improve their potential earnings.
The plan is simple. OpusPoint Partners seeks to form a team of researchers and investors who are passionately advancing the future of medical care. Dr. Lindsay Rosenwald and OpusPoint Partners have pulled together a team to explore, discover then invest funds and resources into emerging companies that have promising projections in the field of life science and healthcare.
OpusPoint Partners and Dr. Lindsay Rosenwald remain upfront of the industry by providing start-up businesses and publicly-traded companies, with the opportunity to make a breakthrough by investing in their companies and providing advisory services. It is their belief that by trying to help these innovative companies, more breakthroughs will occur and healthcare would be delivered easier, consequently impacting the lives of ordinary people.
The commitment displayed by OpusPoint Partners has not gone unrewarded because the company surpassed its performance projections for the past few years and built or improved the financial health of more than twenty companies. Investors have also earned excellent risk adjusted returns giving them recognition in the worlds of drug research and finance.
Dr. Lindsay Rosenwald in conjunction with OpusPoint Partners is dedicated to improving the way in which biotechnology investing is done. Imposing strong moral values followed by practicing strong and fair business practices gives them the opportunity to offer their investors excellent returns but with minimized risk. This unusual business strategy with a straightforward formula has had its own degree of success.
OpusPoint Partners and Dr. Lindsay Rosenwald has remained firm in its drive to practice integrity in order to achieve its short and long term goals. They also actively seek to build working relationships with similarly minded individuals and companies in the investment and biotechnology communities. They are of the belief that strong relationships once established within a framework of trust can be subjected to full disclosure in all dealings and with honest investing.
It has been established that this general field is extremely competitive and it is almost tempting to resort to unethical tactics that would shortchange the clinical trial in order to improve the earnings. OpusPoint Partners is unique because it is committed not to take this route but to stay true and fair to all of its participating investors and employees especially when it comes to the research and later the manufacture of the drugs and their trial processes.
Cougar Biotechnology Inc. was founded by Dr. Lindsay Rosenwald and is still based in Los Angeles. This company is focused on the experimental drugs used in the treatment of cancer. One of these drugs has attracted interest from both researchers and investors because it has been very effective in the treatment of advanced cancer of the prostate. Johnson and Johnson signed a deal on July 10th, 2009 and purchased Cougar Biotech labs for just about one billion dollars.
Dr. Lindsay Rosenwald has amassed more than 17 years investing in biotechnology on Wall Street and holds both finance and medical degrees from Pennsylvania State University and from the Temple University School of Medicine, (respectively). His training allowed for specialization in the establishment and re-capitalization of quite a few public and private biotechnology and life sciences companies.
Mr. Rosenwald’s career included the management of the Aries Funds (1994-2007) and the Orion Fund (2002-2006). The Aries Fund invested more than one billion in the Year 2000 alone while the Orion Fund is a capital fund that invests only in biotechnology with particular emphasis on PIPE’s.
Dr. Lindsay Rosenwald is on the Board of Directors for the Republican Jewish Coalition and has strategically formed connections with key players in the biotechnology financing sector. The future looks promising and it is expected that under Dr. Rosenwald’s leadership that OpusPoint Partners will continue to reap even greater success.
OpusPoint Partners maintains its guiding principle which is for the establishment of a solid conglomeration of healthcare and life science organizations that remain committed to always acting with the integrity that negates taking troublesome short cuts in order to achieve their business objectives.
No related posts.